Europe Radiopharmaceuticals Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (Diagnostic Nuclear Medicine and Therapeutic Nuclear Medicine), Application (Oncology, Cardiology, Neurology, and Others), and End User (Hospitals, Imaging Centers, Academic and Research Centers, and Others)
Market Introduction
Europe consists of five major countries namely Germany, France, UK, Italy, and Spain. Germany is one of the largest market of radiopharmaceuticals. The German Radiation Protection Ordinance and the guidelines on obtaining the special qualification contain regulations. In this ordinance specific numbers are listed for guidance, which, however, do not constitute binding minimum numbers. Moreover, in May 2017, Radiation Protection Act was adopted for the protection against radon in dwellings and better provisions for an emergency. The Radiation Protection Act is supplemented by the Radiation Protection Ordinance, which started from 31 December 2018. Furthermore, in Germany the health insurance is a major aspect of the healthcare industry, approximately 71.4 million Germans covered by statutory health insurance (Gesetzliche Krankenversicherung (GKV)) nearly 8.8 million Germans are covered by private health insurance (Private Krankenversicherung (PKV)) and via state aid. As per the German Federal Statistical Office, data for 2019 total annual healthcare expenditure accounted to US$460 billion (EUR 410 billion). In addition, the investments done by various government and non-government associations are helping radiopharmaceuticals market to grow. For instance, in January 2019, the Advancing Nuclear Medicine consortium, with the help of Nuclear Research and Consultancy Group (NRG), has been awarded an amount of US$ 7.7 million (EUR 6.8 million) subsidy for the development of FIELD-LAB. The Dutch initiative is aimed at accelerating the development and introduction of new radiopharmaceuticals. The ground will develop new nuclear medicines that are expected to take a growing role in the personalized treatment of life-threatening diseases like cancer. Therefore, according to the above-mentioned factors the Europe market for the radiopharmaceuticals is expected to grow in the forecast period.
In case of COVID-19, Europe is highly affected especially France and Russia. The COVID-19 pandemic has profoundly changed hospital activities, including NM practice across Europe. A literature search on PubMed was performed covering COVID-19 studies published up until January 2021. As per the findings, the pandemic strongly challenged NM departments, and a reduction in the workforce has been experienced in every center in Europe. NM departments introduced restriction measures to limit COVID-19 transmission, including rescheduling of non-high-priority procedures. Also, some of the departments experienced a delay in radiopharmaceuticals supply or technical assistance due to COVID-19. As a result, the pandemic resulted in a significant reduction of diagnostic and therapeutic NM procedures and a reduced level of care for patients affected by diseases other than COVID-19, such as cancer or acute cardiovascular disease. The pandemic influenced workflows in a substantial proportion of NM departments. New findings supporting COVID-19 diagnosis are expected to accelerate the growth of radiopharmaceuticals in the region. For instance, as per the research study by Chentao Jin et al., published in the European Journal of Nuclear Medicine and Molecular Imaging in May 2021, positron emission tomography (PET) is expected to offer pathophysiological alternations of COVID-19 and facilitate the clinical management of patients. With the role of PET in the COVID-19, the research studies can also pave the way in combating other epidemics in the future.
Get more information on this report :
Market Overview and Dynamics
The Europe radiopharmaceuticals market is expected to grow from US$ 1,940.54 million in 2021 to US$ 3,442.11 million by 2028; it is estimated to grow at a CAGR of 8.5% from 2021 to 2028. In personalized care, treatment is individualized based on specific biochemical markers detected in patients as well as on the characteristics of their disease condition. Imaging techniques identify patients for particular therapies and optimize patient response to treatment while minimizing side effects. Precision medicine involves the use of an individual’s genomic information to offer them targeted treatment. In recent years, scientists are focusing on pioneering neurogenetics to introduce better therapies and treatment for brain and related disorders. Nuclear medicine is gaining pace gradually, and targeted radionuclide therapy provides efficacious treatment modalities against cancer. The latest innovations involve using radionuclides, new or improved multimodality imaging devices, and several recently marketed radiopharmaceuticals in all medical applications, particularly cardiology, neurology, and oncology. Current developments in self-shielded cyclotrons, video-monitored hot cell designs, improved targets, and automated PET radiopharmaceutical synthesis modules, based on computer-controlled graphic user interphase (GUI), have revolutionized the PET molecular imaging technology for basic biomedical research to accomplish evidence-based personalized medicine. Further advancements in novel PET radiopharmaceutical utilizing automated microfluidic synthesis modules and multifunctional nanoparticles, are likely to improve biomarker discovery, internal dosimetry, immunotherapy, pharmacokinetics, and stem cell tracking in regenerative medicine. The peptide receptor radionuclide therapy (PRRT) is at the forefront of new personalized medicines. The somatostatin analogs used in this technique, which bind selectively to cellular receptors on the neuroendocrine tumor cells, carry a gallium radionuclide that simultaneously emits radiation that kills tumors and makes the analogs visible as well as quantifiable with PET. The end effect of successful and measurable treatment is decreased tumor size and reduced symptoms, along with a halt in tumor progression in many patients. Thus, the use of nuclear medicines in personalized medicine is emerging as a prime future trend in the Europe radiopharmaceuticals market.
Key Market Segments
In terms of type, the diagnostic nuclear medicine segment accounted for the largest share of the Europe radiopharmaceuticals market in 2020. In terms of application, the oncology segment held a larger market share of the Europe radiopharmaceuticals market in 2020. Further, the hospitals segment held a larger share of the Europe radiopharmaceuticals market based on end user in 2020.
Major Sources and Companies Listed
A few major primary and secondary sources referred to for preparing this report on the Europe radiopharmaceuticals market are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Advanced Accelerator Applications; Bayer AG; Bracco Imaging S.p.A; Cardinal Health Inc; Curium; ECZACIBA?I MONROL NUCLEAR PRODUCTS CO.; GENERAL ELECTRIC; Lantheus Medical Imaging, Inc.; Nordion; and NTP RADIOISOTOPES.
Reasons to buy report
- To understand the Europe radiopharmaceuticals market landscape and identify market segments that are most likely to guarantee a strong return
- Stay ahead of the race by comprehending the ever-changing competitive landscape for Europe radiopharmaceuticals market
- Efficiently plan M&A and partnership deals in Europe radiopharmaceuticals market by identifying market segments with the most promising probable sales
- Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment form Europe radiopharmaceuticals market
- Obtain market revenue forecast for market by various segments from 2021-2028 in Europe region.
Europe Radiopharmaceuticals Market Segmentation
Europe Radiopharmaceuticals Market - By Type
- Diagnostic Nuclear Medicine
- SPECT
- PET
- Therapeutic Nuclear Medicine
- Alpha Emitters
- Beta Emitters
- Brachytherapy Isotopes
Europe Radiopharmaceuticals Market - By Application
- Oncology
- Cardiology
- Neurology
- Others
Europe Radiopharmaceuticals Market - By End User
- Hospitals
- Imaging Centers
- Academic and Research Centers
- Others
Europe Radiopharmaceuticals Market - By Country
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Europe Radiopharmaceuticals Market - Company Profiles
- Advanced Accelerator Applications
- Bayer AG
- Bracco Imaging S.p.A
- Cardinal Health Inc
- Curium
- ECZACIBA?I MONROL NUCLEAR PRODUCTS CO.
- GENERAL ELECTRIC
- Lantheus Medical Imaging, Inc.
- Nordion
- NTP RADIOISOTOPES
TABLE OF CONTENTS
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Europe Radiopharmaceuticals Market – By Type
1.3.2 Europe Radiopharmaceuticals Market – By Application
1.3.3 Europe Radiopharmaceuticals Market – By End User
1.3.4 Europe Radiopharmaceuticals Market– By Country
2. Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Europe Radiopharmaceuticals Market– Market Landscape
4.1 Overview
4.2 Europe PEST Analysis
4.3 Experts Opinion
5. Europe Radiopharmaceuticals Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Growing Use of Alpha Radio Immunotherapy for Cancer Treatment
5.1.2 Rising Advancements in Nuclear Imaging Techniques
5.2 Market Restraints
5.2.1 Availability of Alternatives
5.3 Market Opportunities
5.3.1 Escalating Growth in Emerging Countries
5.4 Future Trends
5.4.1 Suring Use of Nuclear Medicines for Personalized Treatment
5.5 Impact Analysis
6. Radiopharmaceuticals Market– Europe Analysis
6.1 Europe Radiopharmaceuticals Market Revenue Forecast and Analysis
7. Europe Radiopharmaceuticals Market Analysis – By Type
7.1 Overview
7.2 Europe Radiopharmaceuticals Market Revenue Share, by Type (2021 and 2028)
7.3 Diagnostic Nuclear Medicine
7.3.1 Overview
7.3.2 Diagnostic Nuclear Medicine: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.3.3 SPECT
7.3.3.1 Overview
7.3.3.2 SPECT: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.3.4 PET
7.3.4.1 Overview
7.3.4.2 PET: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.4 Therapeutic Nuclear Medicine
7.4.1 Overview
7.4.2 Therapeutic Nuclear Medicine: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.4.3 Alpha Emitters
7.4.3.1 Overview
7.4.3.2 Alpha Emitters: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.4.4 Beta Emitters
7.4.4.1 Overview
7.4.4.2 Beta Emitters: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.4.5 Brachytherapy Isotopes
7.4.5.1 Overview
7.4.5.2 Brachytherapy Isotopes: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
8. Europe Radiopharmaceuticals Market Analysis – By Application
8.1 Overview
8.2 Europe Radiopharmaceuticals Market Revenue Share, by Application (2021 and 2028)
8.3 Oncology
8.3.1 Overview
8.3.2 Oncology: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
8.4 Cardiology
8.4.1 Overview
8.4.2 Cardiology: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
8.5 Neurology
8.5.1 Overview
8.5.2 Neurology: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
8.6 Others
8.6.1 Overview
8.6.2 Others: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9. Europe Radiopharmaceuticals Market Analysis – By End User
9.1 Overview
9.2 Europe Radiopharmaceuticals Market Share, by End User, 2021 and 2028, (%)
9.3 Hospitals
9.3.1 Overview
9.3.2 Hospitals: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.4 Imaging Centres
9.4.1 Overview
9.4.2 Imaging Centres: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.5 Academic and Research Centers
9.5.1 Overview
9.5.2 Academic and Research Centers: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.6 Others
9.6.1 Overview
9.6.2 Others: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
10. Europe Radiopharmaceuticals Market – Country Analysis
10.1 Europe: Radiopharmaceuticals Market
10.1.1 Overview
10.1.2 Europe: Radiopharmaceuticals Market, by Country, 2021 & 2028 (%)
10.1.2.1 Germany: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.1.1 Germany: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.1.2 Germany: Radiopharmaceuticals Market, By Type, 2019–2028 (USD Million)
10.1.2.1.2.1 Germany: Radiopharmaceuticals Market, by Diagnostic Nuclear Medicine, 2019–2028 (USD Million)
10.1.2.1.2.2 Germany: Radiopharmaceuticals Market, by Therapeutic Nuclear Medicine, 2019–2028 (USD Million)
10.1.2.1.3 Germany: Radiopharmaceuticals Market, by Application, 2019–2028 (USD Million)
10.1.2.1.4 Germany: Radiopharmaceuticals Market, by End User, 2019–2028 (USD Million)
10.1.2.2 France: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.2.1 France: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.2.2 France: Radiopharmaceuticals Market, By Type, 2019–2028 (USD Million)
10.1.2.2.2.1 France: Radiopharmaceuticals Market, by Diagnostic Nuclear Medicine, 2019–2028 (USD Million)
10.1.2.2.2.2 France: Radiopharmaceuticals Market, by Therapeutic Nuclear Medicine, 2019–2028 (USD Million)
10.1.2.2.3 France: Radiopharmaceuticals Market, by Application, 2019–2028 (USD Million)
10.1.2.2.4 France: Radiopharmaceuticals Market, by End User, 2019–2028 (USD Million)
10.1.2.3 UK: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.3.1 UK: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.3.2 UK: Radiopharmaceuticals Market, By Type, 2019–2028 (USD Million)
10.1.2.3.2.1 UK: Radiopharmaceuticals Market, by Diagnostic Nuclear Medicine, 2019–2028 (USD Million)
10.1.2.3.2.2 UK: Radiopharmaceuticals Market, by Therapeutic Nuclear Medicine, 2019–2028 (USD Million)
10.1.2.3.3 UK: Radiopharmaceuticals Market, by Application, 2019–2028 (USD Million)
10.1.2.3.4 UK: Radiopharmaceuticals Market, by End User, 2019–2028 (USD Million)
10.1.2.4 Italy: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.4.1 Italy: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.4.2 Italy: Radiopharmaceuticals Market, By Type, 2019–2028 (USD Million)
10.1.2.4.2.1 Italy: Radiopharmaceuticals Market, by Diagnostic Nuclear Medicine, 2019–2028 (USD Million)
10.1.2.4.2.2 Italy: Radiopharmaceuticals Market, by Therapeutic Nuclear Medicine, 2019–2028 (USD Million)
10.1.2.4.3 Italy: Radiopharmaceuticals Market, by Application, 2019–2028 (USD Million)
10.1.2.4.4 Italy: Radiopharmaceuticals Market, by End User, 2019–2028 (USD Million)
10.1.2.5 Spain: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.5.1 Spain: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.5.2 Spain: Radiopharmaceuticals Market, By Type, 2019–2028 (USD Million)
10.1.2.5.2.1 Spain: Radiopharmaceuticals Market, by Diagnostic Nuclear Medicine, 2019–2028 (USD Million)
10.1.2.5.2.2 Spain: Radiopharmaceuticals Market, by Therapeutic Nuclear Medicine, 2019–2028 (USD Million)
10.1.2.5.3 Spain: Radiopharmaceuticals Market, by Application, 2019–2028 (USD Million)
10.1.2.5.4 Spain: Radiopharmaceuticals Market, by End User, 2019–2028 (USD Million)
10.1.2.6 Rest of Europe: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.6.1 Rest of Europe: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.6.2 Rest of Europe: Radiopharmaceuticals Market, By Type, 2019–2028 (USD Million)
10.1.2.6.2.1 Rest of Europe: Radiopharmaceuticals Market, by Diagnostic Nuclear Medicine, 2019–2028 (USD Million)
10.1.2.6.2.2 Rest of Europe: Radiopharmaceuticals Market, by Therapeutic Nuclear Medicine, 2019–2028 (USD Million)
10.1.2.6.3 Rest of Europe: Radiopharmaceuticals Market, by Application, 2019–2028 (USD Million)
10.1.2.6.4 Rest of Europe: Radiopharmaceuticals Market, by End User, 2019–2028 (USD Million)
11. Impact Of COVID-19 Pandemic on Europe Radiopharmaceuticals Market
11.1 Europe: Impact Assessment of COVID-19 Pandemic
12. Industry Landscape
12.1 Overview
12.2 Inorganic Growth Strategies
12.2.1 Overview
12.3 Organic Growth Strategies
12.3.1 Overview
13. Company Profiles
13.1 Cardinal Health Inc
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Curium
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 GENERAL ELECTRIC
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Lantheus Medical Imaging, Inc.
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Bayer AG
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Bracco Imaging S.p.A
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 ECZACIBAI MONROL NUCLEAR PRODUCTS CO.
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 Nordion
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 NTP RADIOISOTOPES
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 Advanced Accelerator Applications
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments
14. Appendix
14.1 About The Insight Partners
14.2 Glossary of Terms
LIST OF TABLES
Table 1. Europe Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)
Table 2. Germany: Radiopharmaceuticals Market, By Type – Revenue and Forecast to 2028 (USD Million)
Table 3. Germany Radiopharmaceuticals Market, by Diagnostic Nuclear Medicine – Revenue and Forecast to 2028 (USD Million)
Table 4. Germany Radiopharmaceuticals Market, by Therapeutic Nuclear Medicine – Revenue and Forecast to 2028 (USD Million)
Table 5. Germany: Radiopharmaceuticals Market, by Application – Revenue and Forecast to 2028 (USD Million)
Table 6. Germany: Radiopharmaceuticals Market, by End User– Revenue and Forecast to 2028 (USD Million)
Table 7. France: Radiopharmaceuticals Market, By Type – Revenue and Forecast to 2028 (USD Million)
Table 8. France Radiopharmaceuticals Market, by Diagnostic Nuclear Medicine – Revenue and Forecast to 2028 (USD Million)
Table 9. France Radiopharmaceuticals Market, by Therapeutic Nuclear Medicine – Revenue and Forecast to 2028 (USD Million)
Table 10. France: Radiopharmaceuticals Market, by Application– Revenue and Forecast to 2028 (USD Million)
Table 11. France: Radiopharmaceuticals Market, by End User – Revenue and Forecast to 2028 (USD Million)
Table 12. UK: Radiopharmaceuticals Market, By Type – Revenue and Forecast to 2028 (USD Million)
Table 13. UK Radiopharmaceuticals Market, by Diagnostic Nuclear Medicine – Revenue and Forecast to 2028 (USD Million)
Table 14. UK Radiopharmaceuticals Market, by Therapeutic Nuclear Medicine – Revenue and Forecast to 2028 (USD Million)
Table 15. UK: Radiopharmaceuticals Market, by Application – Revenue and Forecast to 2028 (USD Million)
Table 16. UK: Radiopharmaceuticals Market, by End User– Revenue and Forecast to 2028 (USD Million)
Table 17. Italy: Radiopharmaceuticals Market, By Type – Revenue and Forecast to 2028 (USD Million)
Table 18. Italy Radiopharmaceuticals Market, by Diagnostic Nuclear Medicine – Revenue and Forecast to 2028 (USD Million)
Table 19. Italy Radiopharmaceuticals Market, by Therapeutic Nuclear Medicine – Revenue and Forecast to 2028 (USD Million)
Table 20. Italy: Radiopharmaceuticals Market, by Application– Revenue and Forecast to 2028 (USD Million)
Table 21. Italy: Radiopharmaceuticals Market, by End User– Revenue and Forecast to 2028 (USD Million)
Table 22. Spain: Radiopharmaceuticals Market, By Type – Revenue and Forecast to 2028 (USD Million)
Table 23. Spain Radiopharmaceuticals Market, by Diagnostic Nuclear Medicine – Revenue and Forecast to 2028 (USD Million)
Table 24. Spain Radiopharmaceuticals Market, by Therapeutic Nuclear Medicine – Revenue and Forecast to 2028 (USD Million)
Table 25. Spain: Radiopharmaceuticals Market, by Application – Revenue and Forecast to 2028 (USD Million)
Table 26. Spain: Radiopharmaceuticals Market, by End User– Revenue and Forecast to 2028 (USD Million)
Table 27. Rest of Europe: Radiopharmaceuticals Market, By Type – Revenue and Forecast to 2028 (USD Million)
Table 28. Rest of Europe Radiopharmaceuticals Market, by Diagnostic Nuclear Medicine – Revenue and Forecast to 2028 (USD Million)
Table 29. Rest of Europe Radiopharmaceuticals Market, by Therapeutic Nuclear Medicine – Revenue and Forecast to 2028 (USD Million)
Table 30. Rest of Europe: Radiopharmaceuticals Market, by Application – Revenue and Forecast to 2028 (USD Million)
Table 31. Rest of Europe: Radiopharmaceuticals Market, by End User– Revenue and Forecast to 2028 (USD Million)
Table 32. Recent Inorganic Growth Strategies
Table 33. Recent Organic Growth Strategies
Table 34. Glossary of Terms
LIST OF FIGURES
Figure 1. Europe Radiopharmaceuticals Market Segmentation
Figure 2. Europe Radiopharmaceuticals Market Segmentation, By Country
Figure 3. Europe Radiopharmaceuticals Market Overview
Figure 4. Diagnostic Nuclear Medicine Segment Held the Largest Share of the Market in 2021
Figure 5. The UK to Show Significant Growth During Forecast Period
Figure 6. Europe PEST Analysis
Figure 7. Europe Radiopharmaceuticals Market Impact Analysis of Drivers and Restraints
Figure 8. Europe Radiopharmaceuticals Market– Revenue Forecast and Analysis
Figure 9. Europe Radiopharmaceuticals Market Revenue Share, by Type (2021 and 2028)
Figure 10. Europe Diagnostic Nuclear Medicine: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 11. Europe SPECT: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 12. Europe PET: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 13. Europe Therapeutic Nuclear Medicine: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 14. Europe Alpha Emitters: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 15. Europe Beta Emitters: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 16. Europe Brachytherapy Isotopes: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 17. Europe Radiopharmaceuticals Market Revenue Share, by Application (2021 and 2028)
Figure 18. Europe Oncology: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 19. Europe Cardiology: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 20. Europe Neurology: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 21. Europe Others: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 22. Europe Radiopharmaceuticals Market Share, by End User, 2021 and 2028 (%)
Figure 23. Europe Hospitals: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 24. Europe Imaging Centres: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 25. Europe Academic and Research Centers: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 26. Europe Others: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 27. Europe: Radiopharmaceuticals Market, by Key Country – Revenue (2021) (USD Million)
Figure 28. Europe: Radiopharmaceuticals Market, by Country, 2021 & 2028 (%)
Figure 29. Germany: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)
Figure 30. France: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)
Figure 31. UK: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)
Figure 32. Italy: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)
Figure 33. Spain: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)
Figure 34. Rest of Europe: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)
Figure 35. Impact of COVID-19 Pandemic in European Country Markets
- Advanced Accelerator Applications
- Bayer AG
- Bracco Imaging S.p.A
- Cardinal Health Inc
- Curium
- ECZACIBA?I MONROL NUCLEAR PRODUCTS CO.
- GENERAL ELECTRIC
- Lantheus Medical Imaging, Inc.
- Nordion
- NTP RADIOISOTOPES
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe radiopharmaceuticals market.
- Highlights key business priorities in order to assist companies to realign their business strategies
- The key findings and recommendations highlight crucial progressive industry trends in the Europe radiopharmaceuticals market, thereby allowing players across the value chain to develop effective long-term strategies
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
- Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the radiopharmaceuticals market, as well as those hindering it
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution